PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.06%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.34%. Joel Greenblatt would verify if operating margins keep pace with this top-line surge.
3.06%
Gross profit growth 1.25-1.5x Medical - Pharmaceuticals median of 2.12%. Mohnish Pabrai would see if economies of scale justify the premium growth.
-44.76%
Negative EBIT growth while Medical - Pharmaceuticals median is -3.32%. Seth Klarman would check if external or internal factors caused the decline.
-7.53%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-34.48%
Negative net income growth while Medical - Pharmaceuticals median is -11.43%. Seth Klarman would investigate factors dragging net income down.
-34.48%
Negative EPS growth while Medical - Pharmaceuticals median is -9.48%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-34.48%
Negative diluted EPS growth while Medical - Pharmaceuticals median is -9.34%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
45.54%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 26.78%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
54.62%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 28.88%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
25.47%
3Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 18.53%. Mohnish Pabrai would attribute it to strong near-term market positioning.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
62.16%
Net income/share CAGR of 62.16% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
72.44%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.24%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-3.19%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 1.15%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
187.26%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 86.76% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
123.92%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 26.88%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
56.65%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.34%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
-21.43%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
57.14%
5Y dividend/share CAGR of 57.14% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
22.22%
3Y dividend/share CAGR of 22.22% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
16.28%
AR growth of 16.28% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
8.26%
Inventory growth of 8.26% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
6.92%
Asset growth of 6.92% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.38%
BV/share growth of 3.38% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
75.68%
Debt growth of 75.68% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
6.04%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.